The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels.

The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. Abstract Text:

Gianluca Severi,Vanessa M Hayes,Andrea A Tesoriero,Melissa C Southey,Hoa N Hoang,Emma J D Padilla,Howard A Morris,Dallas R English,Robert L Sutherland,Peter Boyle,John L Hopper,Graham G Giles,

OBJECTIVE: To use a large population-based case-control study to test the association between the common genetic variant rs743572 (-34 T to C), prostate cancer risk and circulating levels of several hormones. SUBJECTS AND METHODS: A previous meta-analysis concluded that reported associations between rs743572 in the promoter of CYP17A1 and prostate cancer risk might reflect publication bias, but a few recent studies reported associations with prostate cancer risk and data suggesting that rs743572 is functional. We genotyped 824 prostate cancer cases and 737 population-based controls, and applied unconditional logistic regression to estimate the association between rs743572 and prostate cancer risk. We also used linear regression of transformed testosterone, androstanediol glucuronide, dehydroepiandrosterone sulphate, androstenedione, sex hormone-binding globulin and oestradiol (circulating levels) measured for controls, to estimate the association between these levels and rs743572. The linear models were adjusted for age and laboratory batch. RESULTS: Men with different genotypes had similar circulating levels of all the hormones measured (all P < 0.05). In the case-control comparison using unconditional unadjusted logistic regression, the odds ratios (95% confidence interval) for prostate cancer were 1.07 (0.87-1.32) and 0.94 (0.71-1.25) for the dominant and recessive models, respectively, and for the co-dominant model, 1.10 (0.88-1.36) and 0.99 (0.73-1.35) for carriers of one or two copies of the C allele, respectively. There was no evidence of heterogeneity in the odds ratios by tumour stage (all P > 0.3) and grade (all P > 0.3). CONCLUSION: The results of the present study are consistent with the conclusions of the previous meta-analysis, and suggest that rs743572 has no role in the risk of prostate cancer for men of Caucasian origin.

The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. Publishing Authors By Initials

G Severi,VM Hayes,AA Tesoriero,MC Southey,HN Hoang,EJ Padilla,HA Morris,DR English,RL Sutherland,P Boyle,JL Hopper,GG Giles,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: BJU international

VOLUME: 101

Page Numbers: 492-6

Journal Abbreviation: BJU Int.

ISSN: 1464-410X

DAY: 6

MONTH: 11

YEAR: 2007

The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100886721

The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels.

AFFILIATION: Cancer Epidemiology Centre, The Cancer Council Victoria, Carlton, Victoria 3053, Australia. gianluca.severi@cancervic.org.au

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: BJU Int

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels Related Publications

• A perspective on telmisartan and cardiovascular risk.
• Adverse childhood experiences and childhood autobiographical memory disturbance.
• Adverse childhood experiences and prescribed psychotropic medications in adults.
• Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor.
• Assessing adaptive behaviour in the post-acute setting following traumatic brain injury: initial reliability and validity of the Adaptive Behaviour and Community Competency Scale (ABCCS).
• Bayesian inference for stochastic epidemic models with time-inhomogeneous removal rates.
• Blood pressure-the better biomarker: delay in clinical application.
• Brain stem gliomas: Patterns of Care in Victoria from 1998-2000.
• Cloretazine for the treatment of acute myeloid leukemia.
• Computational capabilities of recurrent NARX neural networks.
• Expression and regulation of anti-mullerian hormone in an oviparous species, the hen.
• Financial implications of plans to combat methicillin-resistant Staphylococcus aureus (MRSA) in an orthopaedic department.
• Hormone therapy and breast cancer: what factors modify the association?
• Institution of universal screening for Group B streptococcus (GBS) from a risk management protocol results in reduction of early-onset GBS disease in a tertiary obstetric unit.
• Is cancer risk associated with anger control and negative affect? Findings from a prospective cohort study.
• Learning long-term dependencies in NARX recurrent neural networks.
• Nelarabine activity in acute biphenotypic leukemia.
• Nicotine in blood in relation to smoking.
• Occupational exposure to ionizing and non-ionizing radiation and risk of glioma.
• On the distribution of performance from multiple neural-network trials.
• Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
• RECENT CASES OF DENTAL MALPRACTICE.
• Recurrent ectopic pregnancy.
• The cardiometabolic syndrome and calcium channel blocker combination drugs.
• The enduring effects of abuse and related adverse experiences in childhood : A convergence of evidence from neurobiology and epidemiology.
• The management of primary cutaneous melanoma in Victoria in 1996 and 2000.
• The oxygen effect on radiation-induced chromosome aberrations: breakage-versus-recombination hypotheses.
• The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels.
• The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2.
• Treatment of acute lymphoblastic leukaemia : a new era.